Molefy Pharma Presents Its Strategy to Develop New Therapies for Neurodegenerative Diseases Such as ALS
The Spanish company combines pharmaceutical research and development with business capabilities to translate scientific knowledge into new therapeutic opportunities. AP-2, its most advanced program, currently in Phase I, is investigating a new approach to targeting TDP-43 protein dysfunction associated with ALS, with the aim of reversing or curing the disease. Dr. Ana Martínez and Dr. […]